The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

Back to Search
Print
Bookmark Trial

NCT00056368

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Versicor, Inc.
King of Prussia, Pennsylvania, 19406, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Candidiasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16 + years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

CandidiasisStudy Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis NCT00496197
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Little Rock, Arkansas
  4. Los Angeles, California
  5. San Francisco, California
  6. San Francisco, California
  7. Newark, Delaware
  8. Newark, Delaware
  9. Wilmington, Delaware
  10. Washington, District of Columbia
  11. Jacksonville, Florida
  12. Miami, Florida
  13. Orlando, Florida
  14. Orlando, Florida
  15. Orlando, Florida
  16. Atlanta, Georgia
  17. Springfield, Illinois
  18. Springfield, Illinois
  19. Springfield, Illinois
  20. Springfield, Illinois
  21. Baltimore, Maryland
  22. Baltimore, Maryland
  23. Detroit, Michigan
  24. Detroit, Michigan
  25. Royal Oak, Michigan
  26. Minnesota, Minnesota
  27. Butte, Montana
  28. Camden, New Jersey
  29. Albany, New York
  30. Buffalo, New York
  31. Rochester, New York
  32. Greenville, North Carolina
  33. Greenville, North Carolina
  34. Portland, Oregon
  35. Philadelphia, Pennsylvania
  36. Pittsburgh, Pennsylvania
  37. West Reading, Pennsylvania
  38. Charleston, South Carolina
  39. Houston, Texas
  40. Seoul,
  41. Seoul,
  42. Seoul,
  43. Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
CandidiasisThe Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC) NCT00041704
  1. King of Prussia, Pennsylvania
ALL GENDERS
12 Years+
years
MULTIPLE SITES
CandidiasisEarly Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom NCT01202253
  1. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
CandidiasisA Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients NCT01092832
  1. Wuhan, Hubei
  2. Beijing,
  3. Brno,
  4. Hong Kong,
  5. Hong Kong,
  6. Shatin, N.T.,
  7. Budapest,
  8. Budapest,
  9. Budapest,
  10. Colonia Insurgentes Cuicuilco, Delegacion Coyoacan, DF
  11. Ermita,, Manila
  12. Manila,
  13. Olsztyn,
  14. Bratislava,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Official Title  ICMJE A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications.
Brief Summary Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the body.
Detailed Description Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Candidiasis
Intervention  ICMJE
  • Drug: Anidulafungin
  • Drug: Fluconazole
Study Arms  ICMJE Not Provided
Publications * Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007 Jun 14;356(24):2472-82.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 17, 2008)		256
Original Enrollment  ICMJE
 (submitted: June 23, 2005)		297
Actual Study Completion Date  ICMJE October 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE
  • Diagnosis of candidemia and/or other forms of invasive candidiasis.
  • Should not have received greater than 48 hours of systemic antifungal therapy.
  • Life expectancy should be greater than 72 hours.
  • Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00056368
Other Study ID Numbers  ICMJE VER002-9
A8851002
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Vicuron Pharmaceuticals
Investigators  ICMJE Not Provided
PRS Account Pfizer
Verification Date October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP